GlassScriptPhysician profile
Andrew Q Pham
NPI 1659609527
$5,181.07
in general payments reported to CMS, 2019-2025
22 companies · $184 in 2025
The $184 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $100 · 2021: $1,077 · 2022: $1,401 · 2023: $1,393 · 2024: $696 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,273.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $849.07 | 2019-2024 | Dupixent |
| Glaxosmithkline, LLC. | $808.68 | 2021-2024 | Nucala, Trelegy Ellipta |
| Amgen INC. | $721.57 | 2021-2024 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $674.87 | 2019-2025 | Cuvitru, Takhzyro, Fruzaqla |
| Genzyme Corporation | $443.56 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $300.13 | 2021-2024 | Tezspire |
| Abbvie INC. | $281.47 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $201.21 | 2021-2022 | |
| Alk-Abello, INC | $187.80 | 2020-2024 | Grastek, Ragwitek, Odactra |
| Pfizer INC. | $135.79 | 2022-2023 | |
| Exelixis INC. | $125.00 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $112.56 | 2021 | |
| Astellas Pharma US INC | $74.99 | 2021 | |
| Gilead Sciences, INC. | $51.23 | 2021 | |
| Genentech USA, INC. | $46.68 | 2020-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $41.95 | 2021 | |
| Karyopharm Therapeutics INC. | $28.00 | 2020 | |
| Janssen Biotech, INC. | $25.32 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $23.61 | 2021 | |
| Boston Scientific Corporation | $19.60 | 2023 | |
| Grifols USA, LLC | $15.00 | 2024 | Xembify |
| Lilly USA, LLC | $12.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.